/term/shiller-pe-ratio/STU:8AP Agios Pharmaceuticals (STU:8AP) Shiller PE Ratio
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Agios Pharmaceuticals Inc (STU:8AP) » Definitions » Shiller PE Ratio

Agios Pharmaceuticals (STU:8AP) Shiller PE Ratio : (As of Jun. 20, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Agios Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Agios Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Agios Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Agios Pharmaceuticals Shiller PE Ratio Chart

Agios Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Agios Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Agios Pharmaceuticals's Shiller PE Ratio

For the Biotechnology subindustry, Agios Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Agios Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Agios Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Agios Pharmaceuticals's Shiller PE Ratio falls into.



Agios Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Agios Pharmaceuticals's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Agios Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-1.334/131.7762*131.7762
=-1.334

Current CPI (Mar. 2024) = 131.7762.

Agios Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -0.397 100.560 -0.520
201409 0.078 100.428 0.102
201412 -0.616 99.070 -0.819
201503 -0.120 99.621 -0.159
201506 -0.757 100.684 -0.991
201509 -0.953 100.392 -1.251
201512 -0.991 99.792 -1.309
201603 -0.548 100.470 -0.719
201606 -1.308 101.688 -1.695
201609 -1.452 101.861 -1.878
201612 -1.270 101.863 -1.643
201703 -1.459 102.862 -1.869
201706 -1.584 103.349 -2.020
201709 -1.334 104.136 -1.688
201712 -1.529 104.011 -1.937
201803 -1.322 105.290 -1.655
201806 -1.019 106.317 -1.263
201809 -1.397 106.507 -1.728
201812 -1.389 105.998 -1.727
201903 -1.407 107.251 -1.729
201906 -1.655 108.070 -2.018
201909 -1.643 108.329 -1.999
201912 -1.440 108.420 -1.750
202003 -0.534 108.902 -0.646
202006 -1.163 108.767 -1.409
202009 -1.214 109.815 -1.457
202012 -1.159 109.897 -1.390
202103 22.638 111.754 26.694
202106 -1.170 114.631 -1.345
202109 -1.326 115.734 -1.510
202112 -1.540 117.630 -1.725
202203 -1.580 121.301 -1.716
202206 -1.589 125.017 -1.675
202209 -1.505 125.227 -1.584
202212 0.632 125.222 0.665
202303 -1.373 127.348 -1.421
202306 -1.394 128.729 -1.427
202309 -1.537 129.860 -1.560
202312 -1.577 129.419 -1.606
202403 -1.334 131.776 -1.334

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Agios Pharmaceuticals  (STU:8AP) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Agios Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Agios Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Agios Pharmaceuticals (STU:8AP) Business Description

Traded in Other Exchanges
Address
88 Sidney Street, Cambridge, MA, USA, 02139
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development strategy for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.

Agios Pharmaceuticals (STU:8AP) Headlines

No Headlines